- Home
- HCWB vs LRE Comparison
HCWB vs LRE Comparison
Compare HCWB & LRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCWB
- LRE
- Stock Information
- Founded
- HCWB 2018
- LRE 2001
- Country
- HCWB United States
- LRE Japan
- Employees
- HCWB N/A
- LRE N/A
- Industry
- HCWB Biotechnology: Pharmaceutical Preparations
- LRE
- Sector
- HCWB Health Care
- LRE
- Exchange
- HCWB Nasdaq
- LRE Nasdaq
- Market Cap
- HCWB 16.1M
- LRE 17.6M
- IPO Year
- HCWB 2021
- LRE 2023
- Fundamental
- Price
- HCWB $3.73
- LRE $1.80
- Analyst Decision
- HCWB Strong Buy
- LRE
- Analyst Count
- HCWB 1
- LRE 0
- Target Price
- HCWB $35.00
- LRE N/A
- AVG Volume (30 Days)
- HCWB 235.7K
- LRE 15.0K
- Earning Date
- HCWB 08-13-2025
- LRE 01-01-0001
- Dividend Yield
- HCWB N/A
- LRE N/A
- EPS Growth
- HCWB N/A
- LRE N/A
- EPS
- HCWB N/A
- LRE 0.29
- Revenue
- HCWB $1,445,145.00
- LRE $117,804,154.00
- Revenue This Year
- HCWB N/A
- LRE N/A
- Revenue Next Year
- HCWB N/A
- LRE N/A
- P/E Ratio
- HCWB N/A
- LRE $6.12
- Revenue Growth
- HCWB N/A
- LRE 8.82
- 52 Week Low
- HCWB $3.55
- LRE $1.10
- 52 Week High
- HCWB $100.80
- LRE $2.49
- Technical
- Relative Strength Index (RSI)
- HCWB 30.10
- LRE 54.60
- Support Level
- HCWB $3.55
- LRE $1.64
- Resistance Level
- HCWB $5.47
- LRE $2.11
- Average True Range (ATR)
- HCWB 0.57
- LRE 0.14
- MACD
- HCWB -0.03
- LRE -0.01
- Stochastic Oscillator
- HCWB 20.81
- LRE 24.49
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.